Shattuck-Brandt, R. L., Chen, S.-C., Murray, E., Johnson, C. A., Crandall, H., O’Neal, J. F., … Richmond, A. (2023). Table S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. https://doi.org/10.1158/1078-0432.22468076

Shattuck-Brandt, Rebecca L., Sheau-Chiann Chen, Emily Murray, Christopher Andrew Johnson, Holly Crandall, Jamye F. O’Neal, Rami Nayef Al-Rohil, et al. “Table S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition,” March 31, 2023. https://doi.org/10.1158/1078-0432.22468076.

Shattuck-Brandt RL, Chen S-C, Murray E, Johnson CA, Crandall H, O’Neal JF, et al. Table S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 2023.

Shattuck-Brandt, Rebecca L., et al. Table S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22468076.

Shattuck-Brandt RL, Chen S-C, Murray E, Johnson CA, Crandall H, O’Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A. Table S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 2023.